Low-dose decitabine enhances chidamide-induced apoptosis in adult acute lymphoblast leukemia, especially for p16-deleted patients through DNA damage [0.03%]
低剂量地西他滨增强希达仙诱导的成人急性淋巴细胞白血病患者凋亡尤其是对于p16缺失患者的机制研究
Pengcheng Shi,Leisi Zhang,Kai Chen et al.
Pengcheng Shi et al.
Aim: To investigate the combined action of decitabine (DAC) with chidamide (CS055) on acute lymphoblastic leukemia (ALL) cells. Materials & methods: ...
Early health technology assessments in pharmacogenomics: a case example in cardiovascular drugs [0.03%]
药理基因组学的早期卫生技术评估：心血管药物的一个案例分析
Joost W Geenen,Ekaterina V Baranova,Folkert W Asselbergs et al.
Joost W Geenen et al.
Aim: To assess the required characteristics (cost, sensitivity and specificity) of a pharmacogenomic test for being a cost-effective prevention of angiotensin-converting enzyme inhibitors induced angioedema. Furthermore, ...
CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention [0.03%]
基于CYP2C19指导的抗血小板治疗：经皮冠状动脉介入术后30天和1年结果的成本效益分析
Mrudula S Borse,Olivia M Dong,Melissa J Polasek et al.
Mrudula S Borse et al.
Aim: Determine whether using CYP2C19 genotype to optimize antiplatelet therapy selection is cost effective over the initial 30 days and 1-year following percutaneous coronary intervention. ...
Pharmacogenomic considerations in the treatment of muscle-invasive bladder cancer [0.03%]
肌肉浸润性膀胱癌治疗中的药物基因组学考量
Tahlita Cm Zuiverloon,Dan Theodorescu
Tahlita Cm Zuiverloon
Recent advances in next-generation sequencing techniques have greatly improved our understanding of the genomic alterations in bladder cancer. Cisplatin-based chemotherapy provides a viable treatment option in the neoadjuvant, adjuvant and ...
Advanced cancer pain: the search for genetic factors correlated with interindividual variability in opioid requirement [0.03%]
晚期癌症疼痛中与个体之间阿片类药物需求差异相关的遗传因素的研究
Maja Matic,Joost Lm Jongen,Laure Elens et al.
Maja Matic et al.
Aim: To assess association between genetic variants and opioid requirement in cancer patients. Materials & methods: A prospective obser...
Observational Study
Pharmacogenomics. 2017 Aug;18(12):1133-1142. DOI:10.2217/pgs-2017-0060 2017
Association of CYP2C19*2 polymorphism with clopidogrel response and 1-year major adverse cardiovascular events in a multiethnic population with drug-eluting stents [0.03%]
CYP2C19*2多态性与药物洗脱支架植入患者的氯吡格雷反应及一年内主要心血管事件的关系
Shirley Siang Ning Tan,Alan Yean Yip Fong,Melissa Mejin et al.
Shirley Siang Ning Tan et al.
Background: Patients undergoing elective percutaneous coronary intervention (PCI) with drug-eluting stents (DES) who have impaired clopidogrel response, have a higher risk of subsequent major adverse cardiovascular events...
Use of exome sequencing to determine the full profile of genetic variants in the fluoropyrimidine pathway in colorectal cancer patients affected by severe toxicity [0.03%]
应用外显子组测序确定氟尿嘧啶类药物代谢途径基因变异的全貌以影响结直肠癌患者发生严重毒副反应
Marta Pellicer,Xandra García-González,María I García et al.
Marta Pellicer et al.
Aim: To identify genetic variants associated with capecitabine toxicity in fluoropyrimidine pathway genes using exome sequencing. Patients & methods: ...
The effect of rs5758550 on CYP2D6*2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen [0.03%]
rs5758550多态性对乳腺癌患者使用他莫昔芬的CYP2D6*2表型及内源性恩度昔芬生成的影响
Anabel B Sanchez-Spitman,Dirk-Jan Ar Moes,Hans Gelderblom et al.
Anabel B Sanchez-Spitman et al.
Aim: CYP2D6*2 is considered fully active, but it has been suggested that it only happens in the presence of rs5758550. This study aims to elucidate the impact of this enhancer. ...
Anaplastic lymphoma kinase rearrangements in non-small-cell lung cancer: novel applications in diagnostics and treatment [0.03%]
间变性淋巴瘤激酶重排在非小细胞肺癌中的诊断和治疗新应用
Rodney E Shackelford,Junaid M Ansari,Eric X Wei et al.
Rodney E Shackelford et al.
The ALK gene, first identified as an anaplastic large cell lymphoma driver mutation, is dysregulated in nearly 20 different human malignancies, including 3-7% of non-small-cell lung cancers (NSCLC). In NSCLC, ALK commonly fuses with the EML...
Institutional profile of pharmacogenetics within University of Michigan College of Pharmacy [0.03%]
密歇根大学药学院药物基因组学的机构概况
Daniel L Hertz,Jasmine A Luzum,Amy L Pasternak et al.
Daniel L Hertz et al.
The University of Michigan College of Pharmacy has made substantial investment in the area of pharmacogenomics to further bolster its activity in pharmacogenomics research, implementation and education. Four tenure-track faculty members hav...